June, 2010: TxCell announces the successfull completion of the Preclinical Development of TX-RAD in Inflammatory Arthritis

April, 2010: TxCell announces Positive Preliminary Results from the Phase I/IIa clinical trial of OvaSave in Crohn's Disease

January, 2010: TxCell appoints Miguel Forte Chief Medical Officer

July, 2009: The collaboration project with TxCell, TcLand, INSERM U844/CHRU Montpellier, has been approuved by the French Public Institutions for the development of Tr1 cell-based technology in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.